Arsenic trioxide induces differentiation of cancer stem cells in hepatocellular carcinoma through inhibition of LIF/JAK1/STAT3 and NF‐kB signaling pathways synergistically

Xin Zhang,Bo Hu,Yun‐Fan Sun,Xiao‐Wu Huang,Jian‐Wen Cheng,Ao Huang,Hai‐Ying Zeng,Shuang‐Jian Qiu,Ya Cao,Jia Fan,Jian Zhou,Xin‐Rong Yang
DOI: https://doi.org/10.1002/ctm2.335
IF: 8.554
2021-02-01
Clinical and Translational Medicine
Abstract:OBJECTIVE: Differentiation-inducing therapy for tumors is a strategy that aims to induce the differentiation and maturation of cancer stem cells (CSCs). The differentiation-inducing capacity of arsenic trioxide (ATO) in hepatocellular carcinoma (HCC) and the underlying mechanism were previously unknown.METHODS: In the present study, we explored the ATO-induced differentiation of CSCs in HCC by detecting the expression of CSC-related markers and tumorigenicity variation in vivo and in vitro. We developed a combined chemotherapeutic approach to HCC by characterizing the effects of combinatorial treatment with 5-fluorouracil (5-FU)/cisplatin and ATO in vitro and in patient-derived xenograft models. Changes in gene expression patterns were investigated by gene microarray analysis.RESULTS: ATO effectively induced differentiation of CSCs by downregulation of CSC-related genes and suppression of tumorigenicity capability. Combinatorial treatment with ATO and 5-FU/cisplatin significantly enhanced therapeutic effects in HCC cells compared with the treatment with 5-FU/cisplatin alone. Synergistic inhibition of the LIF/JAK1/STAT3 and NF-kB signaling pathways by ATO and 5-FU/cisplatin is a potential molecular mechanism underlying the differentiation effect.CONCLUSIONS: ATO induced the differentiation of HCC CSCs and potentiated the cytotoxic effects of 5-FU/cisplatin through synergistic inhibition of the LIF/JAK1/STAT3 and NF-kB signaling pathways. These results offer new insights for the clinical treatment of HCC.
oncology,medicine, research & experimental
What problem does this paper attempt to address?
The problem that this paper attempts to solve is the differentiation therapy of cancer stem cells (CSCs) in hepatocellular carcinoma (HCC) and its underlying mechanisms. Specifically, the researchers explored the differentiation - inducing ability of arsenic trioxide (ATO) in HCC and whether this ability can be achieved synergistically by inhibiting the LIF/JAK1/STAT3 and NF - κB signaling pathways. In addition, the study also investigated the enhanced effect of the combined treatment of ATO and 5 - fluorouracil (5 - FU)/cisplatin on the cytotoxicity of HCC cells. The main objectives of the paper include: 1. **Determine the differentiation - inducing ability of ATO**: By detecting the expression of CSC - related markers and the changes in tumorigenicity in vitro and in vivo, study whether ATO can effectively induce the differentiation of CSCs in HCC. 2. **Reveal the molecular mechanisms of differentiation induction**: Through gene microarray analysis and functional experiments, explore how ATO induces the differentiation of CSCs by inhibiting the LIF/JAK1/STAT3 and NF - κB signaling pathways. 3. **Evaluate the effect of combined treatment of ATO and chemotherapy drugs**: Through in vitro experiments and patient - derived xenograft models, evaluate the enhanced effect of the combined treatment of ATO and 5 - FU/cisplatin on the cytotoxicity of HCC cells. These research results provide new insights and potential treatment strategies for the clinical treatment of HCC.